Literature DB >> 11150537

Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15.

N Nishi, Y Koezuka, S A Porcelli, H M Pinedo, R J Scheper, G Giaccone.   

Abstract

Natural killer T (NKT) cells have an extremely restricted T-cell receptor repertoire, in man consisting of a Valpha24 chain preferentially paired with a Vbeta11 chain, and play crucial roles in various immune responses. Characterization of circulating Valpha24(+)Vbeta11(+)-T cells is hampered by their low frequencies. The alpha-galactosylceramide KRN7000 was reported to be presented by CD1d to NKT cells. Since dendritic cells (DC) are potent antigen presenting cells, and have been shown to express CD1d, we analyzed whether these cells could efficiently mediate expansion of Valpha24(+)Vbeta11(+)-T cells. During a 7-day co-culture of peripheral blood mononuclear cells and KRN7000-loaded mature monocyte derived DC (moDC) in the presence of interleukin-7 (IL-7) and IL-15, we observed up to 76-fold expansion of Valpha24(+)Vbeta11(+)-T cells. The expanded Valpha24(+)Vbeta11(+)-T cells expressed the cytotoxic molecule granzyme B, showed negligible expression of Fas ligand and could be induced to express high levels of interferon-gamma, while retaining the capacity to produce IL-4. B cells, expressing CD1d, could also present KRN7000, but Valpha24(+)Vbeta11(+)-T cell expansion was only observed in the presence of IL-7 and/or IL-15. Considering the low frequency of circulating Valpha24(+)Vbeta11(+)-T cells, the present method for expansion of Valpha24(+)Vbeta11(+)-T cells using KRN7000-loaded mature moDC will be of value for the further characterization of this unique T cell subset.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150537     DOI: 10.1016/s0022-1759(00)00272-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  23 in total

1.  Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Authors:  Kaoru Nagato; Shinichiro Motohashi; Fumihiro Ishibashi; Kohsuke Okita; Kazuki Yamasaki; Yasumitsu Moriya; Hidehisa Hoshino; Shigetoshi Yoshida; Hideki Hanaoka; Shin-Ichiro Fujii; Masaru Taniguchi; Ichiro Yoshino; Toshinori Nakayama
Journal:  J Clin Immunol       Date:  2012-04-26       Impact factor: 8.317

Review 2.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

Review 3.  Valpha14 NKT cell-mediated anti-tumor responses and their clinical application.

Authors:  Ken-Ichiro Seino; Shin-Ichiro Fujii; Michishige Harada; Shinichiro Motohashi; Toshinori Nakayama; Takehiko Fujisawa; Masaru Taniguchi
Journal:  Springer Semin Immunopathol       Date:  2005-01-14

4.  Heterogeneity in phenotype and function of CD8+ and CD4/CD8 double-negative Natural Killer T cell subsets in sooty mangabeys.

Authors:  Namita Rout; James G Else; Simon Yue; Michelle Connole; Mark A Exley; Amitinder Kaur
Journal:  J Med Primatol       Date:  2010-08       Impact factor: 0.667

5.  NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Authors:  Stephen R Mattarollo; Alison C West; Kim Steegh; Helene Duret; Christophe Paget; Ben Martin; Geoffrey M Matthews; Jake Shortt; Marta Chesi; P Leif Bergsagel; Michael Bots; Johannes Zuber; Scott W Lowe; Ricky W Johnstone; Mark J Smyth
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

6.  CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Dominik Schneidawind; Antonio Pierini; Maite Alvarez; Yuqiong Pan; Jeanette Baker; Corina Buechele; Richard H Luong; Everett H Meyer; Robert S Negrin
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

7.  EBV promotes human CD8 NKT cell development.

Authors:  Yuling He; Ruijing Xiao; Xiang Ji; Li Li; Lang Chen; Jie Xiong; Wei Xiao; Yujuan Wang; Lijun Zhang; Rui Zhou; Xinti Tan; Yongyi Bi; Yan-Ping Jiang; Youxin Jin; Jinquan Tan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

8.  Interleukin (IL)-4 promotes T helper type 2-biased natural killer T (NKT) cell expansion, which is regulated by NKT cell-derived interferon-gamma and IL-4.

Authors:  Akira Iizuka; Yoshinori Ikarashi; Mitsuzi Yoshida; Yuji Heike; Kazuyoshi Takeda; Gary Quinn; Hiro Wakasugi; Masanobu Kitagawa; Yoichi Takaue
Journal:  Immunology       Date:  2007-11-14       Impact factor: 7.397

9.  Interleukins 15 and 12 in combination expand the selective loss of natural killer T cells in HIV infection in vitro.

Authors:  Venkata Ramanarao Parasa; Anbalagan Selvaraj; Rajasekaran Sikhamani; Alamelu Raja
Journal:  Clin Exp Med       Date:  2014-04-20       Impact factor: 3.984

10.  Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop.

Authors:  Mark A Exley; Runhua Hou; Angela Shaulov; Elena Tonti; Paolo Dellabona; Giulia Casorati; Omid Akbari; H Orhan Akman; Edward A Greenfield; Jenny E Gumperz; Jonathan E Boyson; Steven P Balk; S Brian Wilson
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.